All posts by imreal

Pharmaceutical Market Squeezed by Supply Chain Disruption and Lower Research Activity


Strategic Directions International logo

SDi, part of Science and Medicine Group, is the leading research and advisory firm covering the analytical instrumentation market. In their latest report, Pharmaceutical Market Opportunity 2020, SDi evaluates the global analytical instrument market for the pharmaceutical and biotechnology industry amid the COVID-19 crisis.

SDi predicts pressure on pharmaceutical companies stemming from disruptions in the supply chain of active pharmaceutical ingredients in addition to a decrease in new drug development from reduced lab research activity. However, investment into COVID-19 research will drive growth during this period.

With the virus originating in China, closures among major producers of active pharmaceutical inputs (APIs) squeezed the supply of inputs by between 10-20%. India also suspended the export of key ingredients causing shortages around the world and especially in the United States.

The United States responded with legislation designed to encourage the production of domestic APIs. The Securing America’s Medicine Cabinet Act (SAM-C) expands the FDA’s Emerging Technology Program and authorizes $100 million to build centers of excellence for advanced pharmaceutical manufacturing to help therapeutic development and manufacturing in the US.

The combination of pressure from COVID-19 will affect the market on both ends. Research will be limited from the closure of labs. Bioinformatics, the leading research and advisory firm covering the life sciences market, recently conducted a survey showing that 12% of global research labs are fully operational. Half of all research labs are shut down while the rest are running at a reduced capacity. This survey also includes pharma and biotech labs, which are at the forefront of R&D for this industry. Therefore, many drug discovery processes are also hindered by the global outbreak.

However, all is not lost. The race to find a cure for COVID-19 through the development of a reliable vaccine has begun. Currently, there are 155 medicines and 70 vaccines for the novel coronavirus in the development pipeline. Genetic vaccine platforms using DNA/RNA manipulation seems to be leading the race. This type of vaccine can potentially be developed and produced more quickly than traditional vaccines. As SDi’s report shows, all of this would not be possible without analytical instruments at the heart of each discovery.

SDi’s newly published report, titled The 2020 Pharmaceutical Market Opportunity, evaluates the global analytical instrument market for the pharmaceutical and biotechnology industry. The report covers 74 different analytical techniques, categorized into 10 technological segments. The goal of this report is to provide a strategic perspective on the current situation and projected potential for analytical techniques used in pharmaceutical and biotech industries. Amid the coronavirus chaos, the pharma/bio sector is a unique market, as it is both hindered and stimulated by this pandemic. This report will examine the future direction of laboratory sales to pharma/bio, and how they being affected by this sudden macroeconomic impact, at least in the short term.

The 2020 Pharmaceutical Market Opportunity report can be found at https://strategic-directions.com/product/the-2020-pharmaceutical-market-opportunity-report/.

About Strategic Directions International

Strategic Directions International (SDi), part of Science and Medicine Group, is the leading business intelligence firm in the highly specialized field of analytical and life science instruments. Its client list includes virtually every major analytical instrumentation company in the United States, Europe, and Japan. Founded in 1981, the Los Angeles-based company has published hundreds of market reports and provided proprietary consulting services for a multitude of clients.

Share article on social media or email:

Leading Angel Investor Group Hosting 10th HyperAccelerator Program, Targeting Impact Companies


While the program will be open to a variety of impact ventures, RVC is encouraging entrepreneurs to apply that are developing technologies that can aid in the COVID-19 response effort or that could be viable detection or mitigation solutions for future pandemics.

What if venture capitalists had identified and invested in novel solutions to pandemics ten years ago? We would all be in a better place.

Rockies Venture Club (RVC), the largest angel investor group in Colorado, is hosting their next Impact HyperAccelerator program on June 22nd through June 29th, 2020. The program is designed to help seed-stage startups prepare to raise money from venture capital and angel investors. The accelerator consists of a series of intense sessions, following the “Learn – Do – Present and Defend” model in which companies work closely with mentors to develop defensible valuations, venture capital term sheets, capital stack strategies, financial proformas, hypergrowth marketing, due diligence readiness and pitch training. The program’s capstone is a virtual investor Demo Day with 100+ accredited investors and startup supporters in attendance. This Demo Day is followed by RVC’s syndication investment process for those companies that garnered the greatest interest from RVC’s angel investor network.

This iteration of the HyperAccelerator centers on for-profit social or environmental impact companies in sectors such as healthcare, cleantech, education tech, agriculture tech, climate, water, energy and materials science. This summer’s accelerator will be the 10th cohort of the program created by RVC. This HyperAccelerator, however, will be the first to be offered in a completely virtual environment using a variety of collaborative technologies to engage 10 companies and over 50 investor mentors set to take part.

While the program will be open to a variety of impact ventures, RVC is encouraging entrepreneurs to apply that are developing technologies that can aid in the COVID-19 response effort or that could be viable detection or mitigation solutions for future pandemics. Peter Adams, RVC’s Executive Director and Managing Partner at the new Pandemic Impact Fund, added, “It’s clear that the world is at least a decade behind in pandemic preparedness. We have an opportunity now to identify, support, and fund companies that are innovating in pandemic preparation and response with solutions bridging public and private entities.”

While many venture capital funds and private investors are choosing to constrain capital during this period of economic uncertainty, RVC and its network are opting to support early-stage entrepreneurs and startups by remaining active and deploying investments.

Founders or prospective mentors interested in applying to participate or learning more about the RVC Impact HyperAccelerator can visit http://www.hyperaccelerator.org. The deadline for applications is May 15th, 2020.

About the Rockies Venture Club: Rockies Venture Club is the longest-running and one of the largest Angel Groups in the U.S.A., founded in 1985, whose mission is to advance economic development by actively connecting the most promising entrepreneurial companies with Angel investors, venture capitalists, and other community members. Every year Rockies Venture Club offers over 140 educational programs, mastermind groups, Angel forums, and two major conferences for both investors and entrepreneurs.

Share article on social media or email:

“In Depth” With Laurence Fishburne Covers Innovative Products For Those Suffering From Arthritis and Joint Pain


News Image

In the U.S., over 54 million people have arthritis, and more than 1 in 4 adults experience severe joint pain.

Recipient of numerous awards for his noteworthy performances throughout the years, actor Laurence Fishburne is the host of the show “In Depth”. “In Depth” is an informational program that highlights a wide array of topics that affect viewing audiences across the country. Airing soon is an episode taking a turn into the medical field. Experts will discuss innovative products for treating joint and arthritic pain.

In the U.S., over 54 million people have arthritis, and more than 1 in 4 adults experience severe joint pain. For years medications have been a primary treatment for arthritis and joint pain, but now there are more options available.

Arthritis gloves are an alternative for those who have inflammation in their fingers and wrists from rheumatoid arthritis. Heat or cold packs are other options for different forms of arthritis. Heat increases blood flow to areas of discomfort, while cold constricts blood vessels to decrease inflammation. Another alternative for arthritis and joint pain are topical NSAIDs. These anti-inflammatory drugs work directly to reduce the swelling that causes joint pain.

Arthritic and joint pain does not have to be debilitating. Gloves, hot and cold packs, and topical drugs are just some of the treatments available. Experts will further explore Arthritic and joint pain treatment options in the new episode of “In Depth.”

“In Depth” with Laurence Fishburne is cautiously reviewed broadcast to a broader viewing audience. The educational program has accepted multiple awards for its efforts.

Share article on social media or email:

Savoy Foundation’s Third Annual Notte di Savoia Los Angeles Spring…


In response to the devastating impact of COVID-19, the American Foundation of Savoy Orders is re-launching its West Coast spring charity gala – the Third Annual Notte di Savoia Los Angeles- previously…

(PRWeb April 29, 2020)

Read the full story at https://www.prweb.com/releases/savoy_foundations_third_annual_notte_di_savoia_los_angeles_spring_gala_re_launched_as_a_virtual_giving_event_to_benefit_caterinas_club_feeding_5_000_homeless_children/prweb17077612.htm

Ella Louise Barber’s newly released “Growing Christian Bible Study Guide” profoundly tackles Christian virtues that guide believers in their journey of faith


News Image

“Growing Christian Bible Study Guide”: a comprehensive guide that teaches about Christianity, its sacraments, and its philosophy as written and intended by the Lord through His Holy Word. “Growing Christian Bible Study Guide” is the creation of published author Ella Louise Barber.

Barber shares, “‘Growing Christian: Bible Study Guide’ is filled with knowledge of specific areas for Christian growth regarding sin, forgiveness (which many of us need to learn), our tongue (mouth), the world, prayer, and our mindset.

“Christian marriage is more than finding a rich man or gorgeous woman, even marrying for loneliness or saying she’s pregnant. There are biblical principles for marriage and sex. After accepting Jesus and being baptized, you are to grow in your Christianity, and there are stages.

“Learn about DEATH. This rarely discussed and seldom preached about subject for believers and unbelievers alike and a Christian’s life after death. You will be amazed what you will discover about death, perhaps answering some of your questions: Where will my soul live in eternity? Where are my loved ones? Will I ever see them again? Is there really life after death? Does everyone go to heaven? How will I get to heaven? All of these questions and more are answered in ‘Growing Christian: Bible Study Guide.’

“Learn about some whimsical colloquialisms and their origin! Christians and divorce, and are we permitted to marry a spouse we divorced?

“Christians, let us grow in knowledge and understanding of the Word of God.

“Perhaps you may have heard of ‘Ripley’s Believe It or Not.’ Now it is ‘Ella Louise Barber’s Believe It or Not’ when I tell you that sex, working, work ethics, bankruptcy, and much more are in the Bible!”

Published by Christian Faith Publishing, Ella Louise Barber’s new book seeks to strengthen the believers’ wisdom and understanding of their conviction and purpose in Christ to assure the attainment of grace and eternal life.

This book is an exemplary Bible study guide that relates to the heart and mind on ideas commonly talked about as enlightenment-seeking Christians.

View the synopsis of “Growing Christian Bible Study Guide” on YouTube.

Consumers can purchase “Growing Christian Bible Study Guide” at traditional brick-and-mortar bookstores or online at Amazon.com, Apple iTunes store, or Barnes and Noble.

For additional information or inquiries about “Growing Christian Bible Study Guide,” contact the Christian Faith Publishing media department at 866-554-0919.

Share article on social media or email:

PolyU Study Shows One in Eight Not Wearing Face Masks Properly Almost 80% of People Reusing Them


In February, the research team conducted an observational study of 10,211 people in different areas of Hong Kong, recording how people wear their masks. The study found that most people wore face masks when going out (95%) of whom 84% wore disposable surgical masks. However, more than one-eighth (13%) wore their surgical masks incorrectly; major mistakes include: wearing a mask inside-out or upside-down (36%) and wearing it too low exposing their nostrils and/or mouth (43%).

The team has also been conducting an online survey since mid-March to collect local citizens’ views and attitudes on wearing face marks. Among the 2,859 responses collected so far, most respondents (94%) agreed that wearing a face mask could prevent infection and reduce the risk of viral transmission in the community. However, a significant number of respondents said that they would reuse face masks (76%), with people in the 46-65 and >65 age groups showing a higher percentage of reuse.

Despite heightened awareness of the need for prevention of viral spread, many fail to wear their masks properly

According to Dr Shara Lee, Associate Professor of the Department of Health Technology and Informatics who led the study, the majority of the public have been on high alert and have taken effective preventive measures since the outbreak of COVID-19, and wearing face masks is seen as one of the key measures in the fight against the disease. “Our studies found that people have a high awareness of COVID-19 and agree that wearing face masks is an effective way to prevent viral transmission and community outbreak.” said Dr Lee.

Many of them put this into practice by consistently wearing a face mask. However, despite months of public health education, one in eight have not mastered the correct way to wear a surgical mask. Surprisingly, nearly 80% of the respondents said they would reuse them. This shows that reuse of disposable face masks is widely accepted by the public, probably due to reasons such as an inadequate supply, poor awareness a mask’s disposable nature, financial reasons or receiving incorrect information. These factors potentially increase the risk of transmission and infection, and project a false sense of security when people wear a mask in the belief that they are now protected. The situation is worrying.

Page 1

The research team identified some common mistakes when using face masks:

  • Wearing the mask inside-out or upside-down
  • Positioning it too low on the face, exposing the nostrils and/or mouth
  • Touching the outer layer of the mask during use or disposal
  • Pulling down the mask when eating or smoking, or hanging the mask around the neck/other part of the body

Keep up the anti-pandemic effort Do your bit by wearing a face mask correctly

The fight against the COVID-19 outbreak requires perseverance and the cooperation of every member of the public. The research team advises that the public should “do the right thing” by adhering to the proper practices of wearing face masks at all times and keep up the hard-earned effort in containing the community outbreak.

The team also recommends solutions to improve protection from infection due to improper use of face masks, including:


  • Experts formulating comprehensible guidelines for safe handling and storage of face masks for reuse, to minimize the risk of both virus spread and self-contamination
  • Publicity and education on the potential risks of incorrect use of face masks
  • Printing a symbol on the outer layer of the face mask to indicate correct orientation
  • Inclusion of information made available by face mask manufacturers, e.g. a clear visual guide or QR code printed on the box for easier access.

Share article on social media or email:

Brenntag Canada and Fuji Chemical Industries Announce Exclusive Distribution Agreement


News Image

Fuji’s premium line of excipients is produced using their spray drying capabilities and includes Neusilin®, Fujicalin®, F-MELT®, and FujiSil™.


  • Neusilin® – is Magnesium Aluminometasilicate USP/EP/JP. It improves powder flowability, is an excellent adsorbent for oily actives, is an anticaking agent, and acts as a stabilizer for deliquescent drugs.
  • Fujicalin® – is a unique form of Dibasic Calcium Phosphate Anhydrous (DCPA). It provides flowability, rapid disintegration, high direct compressibility, high oil adsorption capability, is non-abrasive, and can improve survivability of probiotics during tableting.
  • F-MELT® – ready-to-use excipient base for ODTs. It provides an easy way to produce fast melt tablets on conventional tableting equipment that disintegrate within 30 seconds. It is directly compressible, extremely flowable, and produces tablets with excellent mouth feel.
  • FujiSil™ – is a unique form of Silicon Dioxide USP/NF. It is a versatile excipient that has superior adsorption properties and can turn oily actives into a free-flowing powder, improve tabletability, be used as a carrier for solid dispersions, and aids in moisture protection.

“The addition of Fuji’s premium line of excipients is a testament to our dedication in strengthening our overall offering to the Canadian Pharmaceutical and Nutraceutical markets,” states Jim Sally, Vice President, Brenntag Canada. “The addition of this product line to our current portfolio and dedicated technical staff gives Brenntag a solid and exciting value proposition for our customers.”

Since 1946, Fuji has been producing excipients at their manufacturing site in Toyama, Japan. These excipients can be used in pharmaceutical, dietary supplement, nutraceutical, personal care, and CBD/cannabis applications.

“We are pleased to add Fuji Chemical’s specialty excipients to the Pharmaceutical and ingredients portfolio at Brenntag. This exclusive agreement will benefit our customer base by providing a local touch to support their development,” said Anne-Marie Gaudet, Pharmaceutical Industry Manager, Brenntag Canada.

About Brenntag:

Brenntag is the global market leader in chemical and ingredients distribution. We connect our suppliers and customers in value-adding partnerships. Our almost 17,500 employees provide tailor-made application, marketing and supply chain solutions. Technical and formulation support, market, industry and regulatory expertise as well as advanced digital tools are just some examples of our services that are aiming to create an excellent customer experience. Our full-line portfolio comprises specialty and industrial chemicals and ingredients of a world-class supplier base. Building on its long-standing experience, unmatched global reach and local excellence, Brenntag works closely alongside its partners to make their business more successful. We are committed to contribute towards greater sustainability in our own business and the industries we serve, and to achieve sustainable profitable growth. Headquartered in Essen (Germany) and with regional headquarters in Philadelphia, Houston and Singapore, Brenntag operates a unique global network with more than 640 locations in 77 countries. The company generated sales of EUR 12.8 billion (USD 14.4 billion) in 2019. Brenntag shares are traded at the Frankfurt Stock Exchange (BNR).

For more information on Brenntag North America, please visit http://www.brenntagnorthamerica.com.

About Fuji Chemical Industries co., LTD, USA, Inc .:

Fuji Chemical Industries Co., Ltd. is engaged in the production and sale of pharmaceutical products/synthesis, the manufacture of pharmaceutical and bulk pharmaceutical products, and the production and sale of food additives. It offers contract manufacturing services that include API manufacturing; functional APIs, such as drug intermediates; and drug products manufacturing. The company also provides excipients and drug delivery systems.

For more information on Fuji Chemical Industries USA, Inc, please visit http://www.fujichemicalusa.com.

Credits: The Brenntag and ConnectingChemistry logos are registered trademarks of Brenntag AG or its subsidiaries. Neusilin®, Fujicalin®, F-MELT® and FujiSil™ are registered trademarks of Fuji Chemical Industries USA, Inc. Any other trademarks are the property of their respective owners.

Share article on social media or email:

Veinlite PEDI2 – A New Age in Pediatric IV Access


The New Veinlite PEDI2

Veinlite PEDI2 offers an 18mm opening (29% larger than PEDI), plus light color selection and brightness control.

The PEDI2 makes intravenous access in children less invasive than ever before.

TransLite LLC, maker of the bestselling Veinlite® brand of vein access devices for healthcare providers, today announced the launch of the all-new PEDI2 for use in pediatric patients.

The Perfect Solution of Reducing Needle Sticks in Children

The PEDI2 was specifically designed to prevent children from suffering multiple sticks during venipuncture procedures. Without the PEDI2, the current Standard of Care is 72.2% first-stick success rate, with some children subjected to several failed attempts. That’s where PEDI2 comes in, representing the cutting edge in pediatric vein access and offering the optimal combination of price, performance, and simplicity.

“No child should have to suffer multiple sticks during medical treatment,” said Nizar Mullani, TransLite LLC’s founder. “The PEDI2 makes intravenous access and blood draws in children much easier, and less invasive than ever before. Every healthcare worker seeks to deliver better patient care, and PEDI2 is the only device that can deliver one-stick success.”

Focus on Continued Innovation

The award-winning Veinlite product line is recognized the world over for its portable, lightweight, and easy to use vein access devices. The PEDI2 takes that legacy of innovation even further. This new model is the result of over two years of design, engineering and prototype development – all focused on delivering the best vein access device for children of all ages (0-17 years). The original Veinlite PEDI was proven to increase first-stick success rate to 93%, making it the most accurate device for pediatrics. TransLite’s goal was to make it even better. PEDI2 outperforms the original PEDI in every way, adding new features like 3-way brightness control, 29% larger opening, and longer battery life. 

Key Features:

  • Clinically proven to improve vein access success rates over Standard of Care
  • 18mm opening reveals larger area for vein imaging
  • Locks vein in place during needle sticks – prevents vein rolling
  • Color selection: orange, red, orange + red
  • 3 levels of brightness control

Helping You Achieve Infection Control Measures

The PEDI2 also meets INS Guidelines for infection control, a critical consideration when providing healthcare treatment to any patient, especially children. Low-cost PEDI2 disposable plastic covers are easy to use and effective in preventing patient-to-provider and patient-to-patient contamination.

Veinlite PEDI2 is available immediately. US customers can purchase direct from the company’s website, veinlite.com (includes an exclusive five-year extended warranty). For customers in other countries and territories, please see Veinlite’s Authorized International Distributors.

To learn more about the new Veinlite PEDI2® – or TransLite’s complete line of IV access and Sclerotherapy vein finders – visit https://www.veinlite.com. For more information or to schedule an interview, contact Katie Schertler at (281) 240-3111 or info(at)veinlite(dot)com

Share article on social media or email:

New Webinar Series From Lachman Consultants Provides Valuable Information To The Pharmaceutical Industry


“These webinars enable Lachman’s team of SMEs and industry experts to bring their unmatched knowledge and expertise to life science organizations at a time when they can benefit from them the most.” – Ricki A. Chase, M.S. Executive Director in the Compliance Practice, Lachman Consultants

Ever a responsive and supportive partner to its clients, these webinars are Lachman Consultants latest effort in providing timely and critical information to life science organizations as they navigate the ever-changing economic and business environment, further complicated by social distancing and health safety concerns.

“Providing the most up-to-date actionable guidance and information has been a keystone of our long-standing client relationships,” commented Ricki A. Chase, M.S. Executive Director in the Compliance Practice, Lachman Consultants, stated. “These webinars enable Lachman’s team of SMEs and industry experts to bring their unmatched knowledge and expertise to life science organizations at a time when they can benefit from them the most.”

The first two webinars in the series focus on FDA inspections. The initial installment, entitled “Preparing for and Handling an FDA Inspection,” will be hosted by Ricki Chase, former FDA Director of the Investigations Branch in the Chicago District. Ricki will be joined by Linda Evans O’Connor, Vice President, Chief of Staff, Lachman Consultants.

The hour-long “Preparing for and Handling an FDA Inspection” webinar will help organizations comprehensively plan for and navigate the various stages, details and technicalities before, during, and after an FDA inspection. Among the topics discussed will be an overview of the FDA and GMPs, FDA Inspections and Enforcement Actions, and the various steps in organizing for an FDA Inspection.

The second Lachman Consultants’ webinar in the series, “How to Respond to Inspectional Observations” will be held on Thursday, May 21st at 2:00 pm EDT and will also be hosted by Ricki Chase, former FDA Director of the Investigations Branch in the Chicago District. Joining her will be Linda Evans O’Connor, Vice President, Chief of Staff, Lachman Consultants. Topics for this webinar will include responding to 483s, summarizing a commitment to sustainable compliance, providing corrective actions, and establishing a practical timeline.

For more information about Lachman Consultants’ webinars, visit: https://www.lachmanconsultants.com/lachman-learning/.

To sign up for “Preparing for and Handling an FDA Inspection,” please go to: https://www.lachmanconsultants.com/lachman-learning/webinar-preparing-for-an-fda-inspection/

To sign up for “How to Respond to Inspectional Observations,” please go to:

https://www.lachmanconsultants.com/lachman-learning/webinar-how-to-respond-to-inspectional-observations/.

2020 © Lachman Consultants

ABOUT LACHMAN CONSULTANTS

Founded in 1978, Lachman Consultants maintains three practice groups: Compliance, Regulatory Affairs, and Science and Technology. Each practice offers industry-leading experience and expertise in its area of focus. Lachman Consultants serves emerging-to-enterprise organizations on a worldwide basis in the Pharmaceutical, Biotechnology, Biologics, Device, and Related Life Science Industries. Lachman Consultants deliver highly effective and proven solutions that include FDA-Related Services, Audits, Quality Assurance & Controls, Scientific and Technical Assistance, Systems Evaluation, and Training, which have been shown to consistently exceed client requirements and expectations.

For additional press information, please contact:

Ilena Della Ventura

Delia Associates

T. 908-534-9044

Share article on social media or email:

Social Distancing Rates Drop for First Time Since COVID-19 Outbreak


Graph shows social distancing index by state

Social Distancing Index by State

The numbers reinforce concerns that warmer weather and public debate over reopening may be spurring a premature loosening of social distancing behavior, even as COVID-19 cases continue to mount.

The COVID-19 outbreak is far from over—but some Americans are jumping the gun when it comes to easing up on social distancing, according to new data from the University of Maryland (UMD).

Researchers at the Maryland Transportation Institute (MTI), part of UMD’s A. James Clark School of Engineering, are reporting a decline in the Social Distancing Index (SDI), starting on April 14, 2020. The SDI is a metric that records compliance with restrictions and guidelines meant to contain the outbreak.

It is the first such decline to be recorded nationwide since the beginning of the COVID-19 pandemic outbreak in the U.S., and comes after successive weeks of the SDI either increasing or holding steady.

The trend is widespread: as of April 24, 2020, 48 states have seen a reduction in their SDI, with the largest drops seen in Louisiana (-15), Ohio (-13), Indiana (-12), Vermont (-12), Alabama (-11), Michigan (-11), Mississippi (-11), North Carolina (-11), and Texas (-11).

The SDI steadily increased in the United States from March 13 through April 13, rising from 14 to 51. On April 14, however, it began to decline. Week-on-week comparisons show a 3-point drop between April 11-17 and the previous week. And the trend has continued, with a further 4-point drop between April 18-24. Nationwide, the index now stands at 44.

The number of work trips has not changed, and the declining SDI is caused mostly by fewer people staying home, more non-work trips, more out-of-state and out-of-county trips, and longer travel distances, according to MTI.

The index is calculated daily by MTI, using anonymized and aggregated location-based service data from mobile phones and other sources. All results at the state and county levels are publicly available on an interactive COVID-19 impact analysis platform created by MTI in partnership with the Center for Advanced Transportation Technology (CATT) Laboratory.

The platform is accessible at: https://data.covid.umd.edu

The numbers reinforce concerns that warmer weather and public debate over reopening may be spurring a premature loosening of social distancing behavior, even as COVID-19 cases continue to mount.

“The real question is what we should do about this observed shift in social distancing momentum,” said Lei Zhang, Herbert Rabin Distinguished Professor and director of MTI, who leads the study. “To those who decided to loosen up and started going out for non-essential purposes, we need to more effectively communicate the importance of social distancing through customized messaging targeting different population groups.”

“To those who are hurt the most by the economic impact and eager to go back to work, governments may need to consider additional assistance especially if we ask them to stay at home for another month or longer.”

###

The A. James Clark School of Engineering at the University of Maryland serves as the catalyst for high-quality research, innovation, and learning, delivering on a promise that all graduates will leave ready to impact the Grand Challenges (energy, environment, security, and human health) of the 21st century. The Clark School is dedicated to leading and transforming the engineering discipline and profession, to accelerating entrepreneurship, and to transforming research and learning activities into new innovations that benefit millions. Visit us online at http://www.eng.umd.edu and follow us on Twitter @ClarkSchool.

Share article on social media or email: